PUBLIC COMPANY
save$SMMTSummit Therapeutics Inc.
$SMMT12.78-4.27%Miami, FL, USupdated 4h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1pre_registration
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- phase3Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- phase3Phase III Study of AK112 for NSCLC Patients
- phase3Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
- phase3Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
🐶 Hiring Signal
next earnings Oct 19, 2026
News
- Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in ChinaSummit Therapeutics and Akeso’s next-generation cancer drug ivonescimab earned an approval in China last week for first-line patients with certain forms of lung cancer. But it came with an updated…endpoints · 11h ago
- Summit, Akeso’s China approval celebration cut short as survival benefit degradesIvonescimab notched its third approval in China last week, but the label update has tempered expectations for the Summit Therapeutics/Akeso drug, showing that progression-free survival declines ove…biospace · 11h ago
- STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefitEurope pulls Tavneos over trial integrity concerns, pricing concerns over AstraZeneca's hypertension drug, and more biotech news from The Readoutstat · 12h ago
- Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combinationAfter keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before quietly scrubbing the ev…fiercebiotech · 19d ago
- As pharma descends on China for deals, BIOSECURE Act raises intellectual property riskWhen signing a biotech licensing deal in China, experts say that pharma’s patent attorneys need to understand the geopolitical risk of the BIOSECURE Act.biospace · 20d ago
- Summit, Merck must navigate new regulatory terrain in China-first cancer landscapeSummit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…biospace · 21d ago
- Summit has less than a year of cash runway left as PD-1/VEGF verdict nearsSummit’s star asset is the PD-1/VEGF bispecific ivonescimab, which this week produced promising survival data from a late-stage global trial in non-small cell lung cancer. The FDA review is ongoing…biospace · 24d ago
- Summit and Akeso sharpen case for ivonescimab with new Western dataSummit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistic…biospace · 26d ago
- STAT+: Pharma tries to tamp down broad China restrictionsAI-focused VC firm raises $800M, Merck's new cholesterol pill, and more biotech news from The Readoutstat · 26d ago
- Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease studyA new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competi…biopharma_dive · 26d ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that